Patrys Limited (AU:PAB) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Patrys Limited has completed a GMP production run of its therapeutic antibody PAT-DX1, with specification testing expected to conclude by July 2024. The company has also presented promising preclinical data suggesting its deoxymabs could be effective in treating vasculitis and other autoimmune diseases. As of June 30, 2024, Patrys reported a cash balance of $2.2 million, with ongoing research and development activities.
For further insights into AU:PAB stock, check out TipRanks’ Stock Analysis page.